4.2 Review

Development of prophylactic vaccines against HIV-1

Journal

RETROVIROLOGY
Volume 10, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1742-4690-10-72

Keywords

-

Categories

Funding

  1. Bill and Melinda Gates Foundation
  2. International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Consortium
  3. Dormeur Investment Services Ltd.
  4. EP Abraham Research Fund
  5. MRC [G0502048, G0000635] Funding Source: UKRI
  6. Medical Research Council [G0000635, G0502048] Funding Source: researchfish

Ask authors/readers for more resources

The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from disease in HIV-1 and other infections strongly suggests that we should not ignore CTL-based research. Here we review recent progress in the field and highlight the challenges implicit in HIV-1 vaccine design and some potential solutions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available